Literature DB >> 8110434

Contribution of vasopressin to orthostatic blood pressure maintenance in essential hypertension.

R B de Paula1, F L Plavnik, C I Rodrigues, F de A Neves, O Kohlmann, A B Ribeiro, I Gavras, H Gavras.   

Abstract

Arginine vasopressin (AVP) has been found to participate in blood pressure maintenance especially when other pressor systems are endogenously or pharmacologically impaired. The purpose of this study was to assess the pressor contribution of AVP to orthostatic blood pressure maintenance in otherwise healthy patients with essential hypertension. Twenty-seven patients were grouped according to age (young n = 13, elderly n = 14) and race (white n = 13, black n = 14). Integrity of autonomic nervous system (ANS) was assessed by Valsalva's maneuver, cold pressor test and head-up tilt. AVP contribution to blood pressure was estimated by the fall in mean arterial pressure in response to IV injection of 0.5 mg of a V1 AVP inhibitor (AVPi). Elderly subjects were found to have a mild (subclinical) ANS impairment as indicated by absence of bradycardia in phase 4 of Valsalva's maneuver and hypotension without concurrent tachycardia during head up tilt. Depressor responses to AVPi while subjects were in the upright position, were greater in elderly and blacks (-15 +/- 11 mm Hg and -15 +/- 12 mm Hg, respectively, P < .05) than young and whites (-8 +/- 6 and -7 +/- 6 mm Hg, respectively, ns). The greater importance of the AVP component in the elderly may be at least partially explained by a mild ANS impairement, whereas hormonal characteristics of hypertension in blacks may explain greater AVPi induced fall in mean arterial pressure. Our data show that both age and race influence the response to AVPi.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8110434     DOI: 10.1093/ajh/6.9.794

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  7 in total

Review 1.  Hypertension and the kidney.

Authors:  D E Wesson
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

2.  Assessing the role of hypothalamic microglia and blood vessel disruption in the development of angiotensin II-dependent hypertension in Cyp1a1-Ren2 rats.

Authors:  Aaron K Korpal; Colin H Brown; Daryl O Schwenke
Journal:  Pflugers Arch       Date:  2018-03-02       Impact factor: 3.657

3.  Exacerbated effects of prorenin on hypothalamic magnocellular neuronal activity and vasopressin plasma levels during salt-sensitive hypertension.

Authors:  Soledad Pitra; Caleb J Worker; Yumei Feng; Javier E Stern
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-07-05       Impact factor: 4.733

Review 4.  Role of Vasopressin in Rat Models of Salt-Dependent Hypertension.

Authors:  Masha Prager-Khoutorsky; Katrina Y Choe; David I Levi; Charles W Bourque
Journal:  Curr Hypertens Rep       Date:  2017-05       Impact factor: 5.369

5.  Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent.

Authors:  Nicole K Littlejohn; Rick B Siel; Pimonrat Ketsawatsomkron; Christopher J Pelham; Nicole A Pearson; Aline M Hilzendeger; Beth A Buehrer; Benjamin J Weidemann; Huiping Li; Deborah R Davis; Anthony P Thompson; Xuebo Liu; Martin D Cassell; Curt D Sigmund; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-27       Impact factor: 3.619

6.  Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model.

Authors:  Mark K Santillan; Donna A Santillan; Sabrina M Scroggins; James Y Min; Jeremy A Sandgren; Nicole A Pearson; Kimberly K Leslie; Stephen K Hunter; Gideon K D Zamba; Katherine N Gibson-Corley; Justin L Grobe
Journal:  Hypertension       Date:  2014-07-07       Impact factor: 10.190

7.  Serum copeptin levels in adolescents with primary hypertension.

Authors:  Edyta Tenderenda-Banasiuk; Anna Wasilewska; Renata Filonowicz; Urszula Jakubowska; Marlena Waszkiewicz-Stojda
Journal:  Pediatr Nephrol       Date:  2013-12-29       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.